Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271016 | 1.00 | ADORA2A (0.72) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL15158228 | 1.00 | ADORA2A (0.72) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| Water SCHEMBL489161 | 0.99 | ADORA2A (0.71) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL15158230 | 0.92 | ADORA2A (0.70) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL271324 | 0.92 | ADORA2A (0.70) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL2367515 | 0.92 | ADORA2A (0.70) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL2883494 | 0.86 | ADORA2A (0.65) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL1985230 | 0.85 | ADORA2A (0.64) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL3949118 | 0.84 | ADORA3 (0.72) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL18556282 | 0.84 | ADORA2A (0.80) | ADORA2AADORA3ADORA2BADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| CN-103415286-A | Compounds and methods for treating pain | AKRON MOLECULES GMBH | 2013-11-27 | — | — | CN | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | ADORA2A 126/4885ADORA3 180/4885ADORA2B 48/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | ADORA2A 126/4885ADORA3 180/4885ADORA2B 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.